Regeneron Pharmaceuticals Shares Sold by Hedge Fund

Wedge Capital Management reduced its stake in the biotech company by 8.6% in Q4 2025

Mar. 28, 2026 at 12:12pm

Got story updates? Submit your updates here. ›

Wedge Capital Management L L P NC, a hedge fund, reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.6% in the fourth quarter of 2025, according to the company's latest 13F filing with the SEC. The fund now owns 41,302 shares of the biopharmaceutical company's stock, valued at $31,880,000.

Why it matters

Regeneron is a major player in the biotech industry, known for its innovative drug discovery technologies. This reduction in ownership by a prominent hedge fund could signal a shift in investor sentiment or portfolio rebalancing, which may impact the stock's performance going forward.

The details

Wedge Capital Management sold 3,893 shares of Regeneron Pharmaceuticals during the fourth quarter. The fund now owns a total of 41,302 shares, down from 45,195 shares held in the previous quarter. Regeneron Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious medical conditions.

  • Wedge Capital Management reduced its Regeneron Pharmaceuticals stake in the fourth quarter of 2025.
  • The hedge fund's 13F filing detailing the share sale was published on March 28, 2026.

The players

Wedge Capital Management L L P NC

A hedge fund that reduced its position in Regeneron Pharmaceuticals by 8.6% in Q4 2025.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company that focuses on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

This reduction in ownership by Wedge Capital Management, a prominent hedge fund, could signal a shift in investor sentiment towards Regeneron Pharmaceuticals. However, the company's innovative drug discovery technologies and focus on serious medical conditions continue to make it an important player in the biotech industry.